Urolithin A

Human supplement literature reported

The guide reports human oral supplement data.

Context: Specific trial and primary identifier are not provided in this entry.

Limitations: This summary is not a primary-source efficacy or PK audit.

Route: Oral · Absolute bioavailability and formulation comparison are not established in this entry.

• Peptide Protocol Field Guide · version 7

Oral daily pattern in supplement literature

Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.

Context: Human · Human supplement trials described in the field guide

Human study regimen: Frequency: Daily; Route: Oral; Species: Human; Population: Human supplement trials described in the field guide

Limitations: No trial identifier, study-specific amount, formulation or duration is supplied. The private supplement-history amount is excluded.

Route: Oral

• Peptide Protocol Field Guide · version 7

Urolithin A in older adults

Administration reported for this specific study or labeled indication.

Context: 66 older adults

Human study regimen: Amount: 1,000 mg; Route: Oral softgels; Frequency: Daily; Duration: 4 months; Species: Human; Population: 66 older adults

Limitations: No significant between-group difference in six-minute walk distance or maximal ATP production. Muscle endurance was a separate endpoint.

Route: Oral softgels

• Urolithin A in older adults ↗

Urolithin A in middle-aged adults

Administration reported for this specific study or labeled indication.

Context: Middle-aged adults

Human study regimen: Amount: 500 or 1,000 mg; Route: Oral; Frequency: Daily; Duration: 4 months; Species: Human; Population: Middle-aged adults

Limitations: Randomized dose arms with a placebo comparator. Muscle strength findings and other exercise endpoints should be interpreted separately.

Route: Oral

• Urolithin A in middle-aged adults ↗